276, 3123-3129). In the current study, we sought to define the mechanism behind this adaptive response. We show that GnRH induces a rapid and dramatic increase in InsP 3 receptor polyubiquitination and that proteasome inhibitors block InsP 3 receptor down-regulation and cause the accumulation of polyubiquitinated receptors. Thus, the ubiquitin/proteasome pathway is active in ␣T3-1 cells, and GnRH regulates the levels of InsP 3 receptors via this mechanism. Given these findings and further characterization of this system, we also examined the possibility that ␣T3-1 cells could be used to examine the ubiquitination of exogenous InsP 3 receptors introduced by cDNA transfection. This was found to be the case, since exogenous wild-type InsP 3 receptors, but not bindingdefective mutant receptors, were polyubiquitinated in a GnRH-dependent manner, and agents that inhibited the polyubiquitination of endogenous receptors also inhibited the polyubiquitination of exogenous receptors. Further, we used this system to determine whether phosphorylation was involved in triggering InsP 3 receptor polyubiquitination. This was not the case, since mutation of serine residues 1588 and 1755 (the predominant phosphorylation sites in the type I receptor) did not inhibit polyubiquitination. In total, these data show that the ubiquitin/proteasome pathway is active in anterior pituitary cells, that this pathway targets both endogenous and exogenous InsP 3 receptors in GnRH-stimulated ␣T3-1 cells, and that, in contrast to the situation for many other substrates, phosphorylation does not trigger InsP 3 receptor polyubiquitination.